These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 30829432)

  • 1. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".
    Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):359-61. PubMed ID: 24840727
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma.
    Param NJ; Bramel ER; Sia D
    Surg Pathol Clin; 2022 Sep; 15(3):529-539. PubMed ID: 36049834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
    Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
    Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.
    Uson Junior PLS; Borad MJ
    Semin Liver Dis; 2023 May; 43(2):218-225. PubMed ID: 36882151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
    Raggi C; Invernizzi P; Andersen JB
    J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathogenesis of intrahepatic cholangiocarcinoma.
    Andersen JB
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):101-13. PubMed ID: 25174625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
    Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K
    Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
    Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholangiocarcinoma.
    Krasinskas AM
    Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging pathways for precision medicine in management of cholangiocarcinoma.
    Rahnemai-Azar AA; Abbasi A; Acher AW; Weber SM; Pawlik TM
    Surg Oncol; 2020 Dec; 35():47-55. PubMed ID: 32827952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
    Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
    Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and molecular abnormalities in cholangiocarcinogenesis.
    Hassid VJ; Orlando FA; Awad ZT; Tan D; Khoury T; Ahmed BH; Alrawi SJ
    Anticancer Res; 2009 Apr; 29(4):1151-6. PubMed ID: 19414358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.